Analysts expect that Theravance Biopharma Inc (NASDAQ:TBPH) will announce earnings of ($1.19) per share for the current quarter, according to Zacks. Two analysts have provided estimates for Theravance Biopharma’s earnings. The highest EPS estimate is ($0.97) and the lowest is ($1.40). Theravance Biopharma posted earnings per share of ($1.27) during the same quarter last year, which would indicate a positive year over year growth rate of 6.3%. The firm is scheduled to report its next earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Theravance Biopharma will report full-year earnings of ($4.39) per share for the current financial year, with EPS estimates ranging from ($4.76) to ($3.90). For the next fiscal year, analysts expect that the business will post earnings of ($3.73) per share, with EPS estimates ranging from ($4.11) to ($3.34). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Theravance Biopharma.
Several research analysts have issued reports on TBPH shares. Needham & Company LLC reissued a “buy” rating on shares of Theravance Biopharma in a research report on Tuesday, December 5th. BidaskClub raised Theravance Biopharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, January 20th. ValuEngine cut Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Leerink Swann raised their target price on Theravance Biopharma from $45.00 to $48.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. Finally, Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $42.00.
Theravance Biopharma (TBPH) opened at $29.45 on Tuesday. The stock has a market capitalization of $1,555.84, a PE ratio of -5.40 and a beta of 1.78. The company has a debt-to-equity ratio of 1.94, a current ratio of 6.05 and a quick ratio of 5.79. Theravance Biopharma has a 12-month low of $22.90 and a 12-month high of $43.44.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.